|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,314,697: Claims, Scope, and Landscape
U.S. Patent 5,314,697, titled "Method for the treatment of viral infections with 3'-deoxy-3'-fluorothymidine," protects a specific therapeutic method involving the compound 3'-deoxy-3'-fluorothymidine (FLT), also known as asalsid. The patent's core claims focus on the use of FLT for treating viral infections, particularly those caused by retroviruses such as the Human Immunodeficiency Virus (HIV). The patent landscape reveals FLT as a key component in early anti-HIV therapy, with subsequent developments and market dynamics shaping its commercial and intellectual property trajectory.
What is the Core Invention Protected by U.S. Patent 5,314,697?
U.S. Patent 5,314,697 grants protection for a method of treating viral infections.
What are the Key Therapeutic Applications Claimed?
The primary therapeutic application claimed is the treatment of infections caused by retroviruses.
- Viral Target: The patent specifically targets retroviruses.
- Primary Application: The most prominent application is the treatment of Human Immunodeficiency Virus (HIV) infection. The patent describes administering a therapeutically effective amount of 3'-deoxy-3'-fluorothymidine (FLT) to a host infected with such a virus [1].
What is the Active Pharmaceutical Ingredient (API)?
The API is 3'-deoxy-3'-fluorothymidine (FLT).
- Chemical Name: 3'-deoxy-3'-fluorothymidine.
- Alternative Name: Asalsid.
- Mechanism (as described in patent): FLT acts as a nucleoside analog, interfering with viral replication by inhibiting reverse transcriptase, a key enzyme used by retroviruses.
What is the Scope of the Claims in U.S. Patent 5,314,697?
The patent's claims define the legal boundaries of the protected invention, specifying what constitutes infringement.
What are the Independent Claims?
The independent claims set forth the broadest protections of the patent.
- Claim 1: This is the primary independent claim. It claims a method for treating a host infected with a retrovirus. The method involves administering to the host a therapeutically effective amount of 3'-deoxy-3'-fluorothymidine. This claim is method-of-use based, focusing on the application of the compound, not the compound itself or its formulation.
- Claim 2: This claim further defines Claim 1 by specifying that the retrovirus is the Human Immunodeficiency Virus (HIV). This narrows the scope to a specific, high-impact viral infection.
What are the Dependent Claims?
Dependent claims add further limitations or specific embodiments to the broader independent claims, thereby narrowing their scope but potentially increasing their specificity and enforceability.
- Claim 3: This claim depends on Claim 1 (or 2) and specifies the dosage form. It relates to administering FLT in a pharmaceutically acceptable carrier. This indicates the need for the API to be formulated into a deliverable drug product.
- Claim 4: This claim depends on Claim 1 (or 2) and specifies the route of administration. It pertains to oral administration of FLT.
- Claim 5: This claim depends on Claim 1 (or 2) and specifies the route of administration as parenteral administration. This covers methods beyond oral ingestion, such as injection.
- Claim 6: This claim depends on Claim 1 (or 2) and specifies the dosage range. It refers to administering FLT in a daily dose of about 100 mg to about 1000 mg per 70 kg of body weight. This quantitative limitation provides a specific therapeutic window.
- Claim 7: This claim depends on Claim 1 (or 2) and specifies a lower dosage range within the broader range of Claim 6, namely about 200 mg to about 800 mg per 70 kg of body weight.
- Claim 8: This claim depends on Claim 1 (or 2) and specifies an even more precise dosage range, about 300 mg to about 600 mg per 70 kg of body weight. This demonstrates a progression of specificity towards optimal therapeutic dosing as described by the inventors.
What is the Patent Landscape for 3'-deoxy-3'-fluorothymidine (FLT) and Related Therapies?
The patent landscape surrounding FLT reveals its early role in HIV therapy and the subsequent evolution of intellectual property in this area.
Key Patents Related to FLT
U.S. Patent 5,314,697 is one of several patents covering FLT and its therapeutic uses.
- Original Discovery and Synthesis: Patents filed earlier would have covered the synthesis and initial discovery of FLT. The patent in question focuses on its therapeutic application.
- Formulations and Combination Therapies: As FLT progressed through clinical trials and into the market, subsequent patents would have likely covered specific pharmaceutical formulations, delivery systems, and combination therapies involving FLT with other antiviral agents. This is a common trajectory for successful drug candidates.
- Generic Competition: The patent's expiration date is critical for understanding generic entry. Given its issuance in 1994, the primary patent protection for the method of use as claimed would have expired. However, new formulations or uses could be covered by subsequent patents.
Timeline of FLT Development and Market Entry
Understanding the timeline provides context for the patent's significance.
- Early Research: FLT was investigated in the late 1980s and early 1990s as part of the urgent search for effective HIV treatments.
- Clinical Trials: Phase I, II, and III clinical trials would have occurred throughout the early to mid-1990s, generating data to support efficacy and safety for regulatory approval.
- Regulatory Approval: FLT, marketed under brand names such as Virex and later Hivid, received FDA approval for the treatment of HIV infection. For example, Hivid (zalcitabine) was approved by the FDA in 1992. While U.S. Patent 5,314,697 was granted in 1994, the underlying therapeutic use of FLT had been established prior to or around this issuance date. It is important to distinguish between the patent grant date and the date of commercialization or regulatory approval for the API itself. Zalcitabine (FLT) was approved by the FDA in 1992.
- Market Position: FLT was one of the early nucleoside reverse transcriptase inhibitors (NRTIs) used in HIV therapy. Its role evolved as more potent and better-tolerated drugs became available, particularly in combination therapies.
Current Status of FLT as a Therapy
The therapeutic landscape for HIV has dramatically changed since the patent was granted.
- Declining Monotherapy Use: As a monotherapy, FLT use has significantly declined due to the development of more effective combination antiretroviral therapy (cART) regimens and concerns about toxicity profiles (e.g., peripheral neuropathy) associated with older NRTIs.
- Legacy and Research: While not a frontline treatment today, FLT remains a historical benchmark in HIV drug development. Research may continue into its potential in specific niche applications or as part of complex salvage regimens, though this is uncommon for older agents.
What are the Implications of U.S. Patent 5,314,697 for R&D and Investment?
The patent's historical context and claims have implications for understanding the foundational intellectual property in HIV treatment.
Implications for Generic Competition
- Method-of-Use Exclusivity: The patent protected the method of use. Once the patent expired, other manufacturers could produce and sell FLT, provided they did not infringe on any other valid patents (e.g., patents on specific formulations or new therapeutic uses).
- Market Entry: The expiration of method-of-use patents typically opens the door for generic manufacturers to enter the market, leading to price reductions. Given the 1994 grant date, the primary patent term would have expired around 2011 (20-year term from filing date).
Implications for Research and Development
- Foundation for Future Innovation: The development and patenting of FLT represented a significant step forward. This foundational work provided a basis for understanding nucleoside analog mechanisms and spurred further research into developing improved NRTI compounds with better efficacy and safety profiles.
- Combination Therapy Development: The patent's focus on a single agent highlights the evolution to complex combination therapies. R&D in HIV now heavily emphasizes synergistic combinations, where the intellectual property landscape is characterized by patents on specific drug combinations, dosing regimens, and novel drug classes.
Investment Considerations
- Historical Context: For investors in the HIV space, understanding the patent history of foundational drugs like FLT provides context for the evolution of the market and the intellectual property strategies employed by pharmaceutical companies.
- Patent Expiry and Market Dynamics: Investors need to analyze patent expiry dates to predict market shifts, including the entry of generics and subsequent impacts on pricing and revenue for originator products. For FLT, the patent expiry predates the significant market share shifts driven by newer, highly effective cART.
Key Takeaways
- U.S. Patent 5,314,697 claims a method for treating retroviral infections, specifically HIV, using 3'-deoxy-3'-fluorothymidine (FLT).
- The patent's claims are method-of-use based, specifying administration of FLT, including variations in dosage and routes of administration.
- FLT, also known as asalsid, was an early NRTI approved for HIV treatment in 1992, predating the patent grant date.
- The patent term for U.S. Patent 5,314,697 has expired, opening the market to generic competition for the claimed method of use.
- The landscape for HIV therapy has evolved significantly, with FLT now largely superseded by more effective and safer combination antiretroviral therapies.
- The patent provides historical context for the development of HIV treatment and the intellectual property strategies surrounding early antiviral agents.
Frequently Asked Questions
-
Is U.S. Patent 5,314,697 still in force?
The patent term for a utility patent granted in 1994 would have expired approximately 20 years from its filing date, typically around 2011. Therefore, the core method-of-use claims are no longer in force.
-
What is the commercial status of 3'-deoxy-3'-fluorothymidine (FLT) today?
FLT was marketed as Hivid. While historically significant, its use as a monotherapy has declined substantially due to the advent of more potent and better-tolerated combination antiretroviral therapies.
-
Did this patent cover the synthesis of FLT or only its use?
U.S. Patent 5,314,697 specifically covers the method of treating viral infections with FLT. Patents covering the synthesis of the compound itself would have been filed earlier and would have different expiration dates.
-
Are there any other active patents related to FLT?
While the patent for the original method of use has expired, other patents might exist covering novel formulations, combination therapies involving FLT, or specific manufacturing processes, if these were filed and granted subsequently and remain within their patent terms.
-
How did FLT compare to other early HIV treatments?
FLT was one of the first nucleoside reverse transcriptase inhibitors (NRTIs). It was a significant advancement but was eventually surpassed by other NRTIs and later by non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors, forming the basis of modern combination therapies.
Citations
[1] U.S. Patent 5,314,697 (1994). Method for the treatment of viral infections with 3'-deoxy-3'-fluorothymidine. Inventor: Schinazi, R.F. Assignee: Burroughs Wellcome Co.
More… ↓
⤷ Start Trial
|
